Back to Search
Start Over
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
- Source :
-
Leukemia & Lymphoma . Jun2019, Vol. 60 Issue 6, p1438-1446. 9p. - Publication Year :
- 2019
-
Abstract
- The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3Kδ inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p <.0001; C-statistic 0.706). Of CLL-IPI factors, age >65, β2-microglobulin >3.5mg/L, unmutated immunoglobulin heavy chain variable region gene, and deletion 17p/TP53 mutation were independently prognostic, but Rai I-IV or Binet B/C was not. The CLL-IPI is prognostic for survival in relapsed CLL and with idelalisib therapy. However, low/intermediate risk is uncommon, and regression parameters of individual factors in this risk-weighted model appear different in relapsed CLL. Reassessment of the weighting of the individual variables might optimize the model in this setting. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CHRONIC lymphocytic leukemia
*IMMUNOGLOBULIN heavy chains
*DELETION mutation
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 60
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 136806999
- Full Text :
- https://doi.org/10.1080/10428194.2018.1540782